Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Other Postretirement Benefit (OPEB) Plans by Quarter
Other Postretirement Benefit (OPEB) Plans — Service Cost ($M) ($M)
Merck Other Postretirement Benefit (OPEB) Plans: $11M in Q2 2026, up 22.2% from a year earlier.
Latest, Q2 2026
11
Period ended Jun 30, 2026
Change on a year earlier
+22.2%
9 in Q2 2025
History
38 quarters
Since Q1 2017
Sources
33
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-07) ↗
Reported in Form 10-Q / 10-K Employee Benefit Plans Note.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Merck Other Postretirement Benefit (OPEB) Plans ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/db-opeb-svc
See every metric in the Merck KPI table. Data updated Oct 26, 2026.